Ionis Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ionis Pharmaceuticals, Inc.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
- Drug Delivery
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Akcea Therapeutics, Inc.
- Regulus Therapeutics, Inc.
- Symphony GenIsis, Inc.
- Isis Pharmaceuticals, Inc.